Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients

被引:188
作者
Rallon, Norma I. [1 ]
Naggie, Susanna [2 ]
Benito, Jose M. [1 ]
Medrano, Jose [1 ]
Restrepo, Clara [1 ]
Goldstein, David [3 ]
Shianna, Kevin V. [3 ]
Vispo, Eugenia [1 ]
Thompson, Alex [2 ]
McHutchison, John [2 ]
Soriano, Vincent [1 ]
机构
[1] Hosp Carlos III, Dept Infect Dis, Madrid 28029, Spain
[2] Duke Clin Res Inst, Durham, NC USA
[3] Inst Genome Sci & Policy, Durham, NC USA
关键词
genetic polymorphism; hepatitis C virus treatment; HIV/hepatitis C virus coinfection; interferon-lambda; IL-28B; pegylated interferon; rs12979860; single nucleotide polymorphism; HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSIENT ELASTOGRAPHY; LIVER FIBROSIS; INTERFERON-ALPHA; INFECTION; IL28B; PREDICTORS; CLEARANCE; DIAGNOSIS; HIV;
D O I
10.1097/QAD.0b013e3283391d6d
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Given that peginterferon-ribavirin treatment is poorly tolerated, there is interest in the identification of predictors of response, particularly in HIV/hepatitis C virus (HCV)-coinfected patients that respond less than HCV-monoinfected individuals. A single nucleotide polymorphism (SNP) near the IL28B gene (rs12979860) has been shown to predict treatment response in HCV-monoinfected patients carrying genotype 1. Information is lacking for HIV/HCV-coinfected individuals and/or other HCV genotypes. Methods: From 650 HIV/HCV-coinfected patients, we identified those who had completed a course of peginterferon-ribavirin therapy with a validated outcome and available repository DNA. The rs12979860 SNP was examined in a blinded fashion. Results: A total of 164 patients were included in the final IL28B genotyping analysis, 90 (55%) of whom achieved sustained virological response (SVR). HCV genotype distribution was as follows: HCV-1 58%, HCV-3 31% and HCV-4 11%. Overall, the SVR rate was higher in patients with CC than in those CT/TT genotypes: 56 of 75 (75%) versus 34 of 89 (38%) (P < 0.0001). The effect of the SNP was seen in HCV genotypes 1 and 4 but not in HCV genotype 3 carriers. In the multivariable analysis (odds ratio; 95% confidence interval; P value), the rs12979860 CC genotype was a strong predictor of SVR (3.7; 1.6-8.5; 0.002), independent of HCV genotype 3 (8.0; 3.1-21.0; < 0.001), serum HCV-RNA less than 600 000 IU/ml (11.9; 3.8-37.4; < 0.001) and lack of advanced liver fibrosis (3.5; 1.4-8.9; 0.009). Conclusion: The rs12979860 SNP located near the IL28B gene is associated with HCV treatment response in HIV-infected patients with chronic hepatitis C due to genotypes 1 or 4. Thus, IL28B genotyping should be considered as part of the treatment decision algorithm in this difficult-to-treat population. (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
引用
收藏
页码:F23 / F29
页数:7
相关论文
共 22 条
[1]   Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C [J].
Castéra, L ;
Vergniol, J ;
Foucher, J ;
Le Bail, B ;
Chanteloup, E ;
Haaser, M ;
Darriet, M ;
Couzigou, P ;
De Lédinghen, V .
GASTROENTEROLOGY, 2005, 128 (02) :343-350
[2]   Hepatitis C Virus (HCV) Genotype 1 Subtype Identification in New HCV Drug Development and Future Clinical Practice [J].
Chevaliez, Stephane ;
Bouvier-Alias, Magali ;
Brillet, Rozenn ;
Pawlotsky, Jean-Michel .
PLOS ONE, 2009, 4 (12) :1-9
[3]  
de Lédinghen V, 2006, JAIDS-J ACQ IMM DEF, V41, P175
[4]   Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance [J].
Ge, Dongliang ;
Fellay, Jacques ;
Thompson, Alexander J. ;
Simon, Jason S. ;
Shianna, Kevin V. ;
Urban, Thomas J. ;
Heinzen, Erin L. ;
Qiu, Ping ;
Bertelsen, Arthur H. ;
Muir, Andrew J. ;
Sulkowski, Mark ;
McHutchison, John G. ;
Goldstein, David B. .
NATURE, 2009, 461 (7262) :399-401
[5]   Diagnosis, Management, and Treatment of Hepatitis C: An Update [J].
Ghany, Marc G. ;
Strader, Doris B. ;
Thomas, David L. ;
Seeff, Leonard B. .
HEPATOLOGY, 2009, 49 (04) :1335-1374
[6]   Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis [J].
Graham, CS ;
Baden, LR ;
Yu, E ;
Mrus, JM ;
Carnie, J ;
Heeren, T ;
Koziel, MJ .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (04) :562-569
[7]   Treatment predictors of a sustained virologic response in hepatitis B and C [J].
Kau, Annika ;
Vermehren, Johannes ;
Sarrazin, Christoph .
JOURNAL OF HEPATOLOGY, 2008, 49 (04) :634-651
[8]   Assessment of Liver Fibrosis by Transient Elastography in Persons with Hepatitis C Virus Infection or HIV-Hepatitis C Virus Coinfection [J].
Kirk, Gregory D. ;
Astemborski, Jacquie ;
Mehta, Shruti H. ;
Spoler, Chuck ;
Fisher, Cedric ;
Allen, Danisha ;
Higgins, Yvonne ;
Moore, Richard D. ;
Afdhal, Nezem ;
Torbenson, Michael ;
Sulkowski, Mark ;
Thomas, David L. .
CLINICAL INFECTIOUS DISEASES, 2009, 48 (07) :963-972
[9]   IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex [J].
Kotenko, SV ;
Gallagher, G ;
Baurin, VV ;
Lewis-Antes, A ;
Shen, ML ;
Shah, NK ;
Langer, JA ;
Sheikh, F ;
Dickensheets, H ;
Donnelly, RP .
NATURE IMMUNOLOGY, 2003, 4 (01) :69-77
[10]   Medical progress: Hepatitis C virus infection. [J].
Lauer, GM ;
Walker, BD .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (01) :41-52